One of the companies pushing forward with a coronavirus treatment has announced how much it will cost for patients.
Gilead Sciences announced remdesivir will cost on average $3,120 for a patient in the U.S. with private insurance, CNBC reported.
Gilead will sell developed countries, including the U.S., vials for $390 each. Private insurance will be charged $520 a vial. The two price points mean government programs such as Medicare will be charged less than private insurance.
A patient will get five-day treatment consisting of six vials. That brings the government cost to $2,340 or $3,120 for a patient with commercial insurance, CNBC reported.
If a patient needed a longer treatment, they could be expected to be charged $4,290 for Medicare patients or $5,720 for privately insured patients, The Wall Street Journal reported.
Gilead stands by the pricetag saying $390 is “well below” the value of remdesivir, CNBC reported.
© 2020 Cox Media Group